Anti-angiogenic therapy using the multi-tyrosine kinase inhibitor Regorafenib enhances tumor progression in a transgenic mouse model of ß-cell carcinogenesis.
Maren Juliane EgidiSebastian KrugJohannes HaybaeckPatrick MichlHeidi GriesmannPublished in: British journal of cancer (2023)
Our data identify important tumor cell-autonomous and stroma-dependent mechanisms of resistance to antiangiogenic therapies.